Because D2R expression on the surface of SCLC tumour-associated endothelial cells decreases as the tumours developed resistance to chemotherapy, we evaluated whether D2R agonist treatment affected the expression patterns of D2R in this context. Here, DRD2 is linked to small cell lung carcinoma.